Filing Flows › Travere Therapeutics (TVTX) › R&D spending
Travere Therapeutics (TVTX) R&D spending by quarter
Travere Therapeutics' R&D spending was $70.3M in Q3 2026 (third quarter 2026), +17% from Q2 2026. Over the last 7 quarters it ranged from $46.9M (Q1 2025) to $70.3M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $70.3M | +17% | +35% |
| Q2 2026 | $60.3M | +6% | +22% |
| Q1 2026 | $57.1M | -1% | +22% |
| Q4 2025 | $57.9M | +12% | — |
| Q3 2025 | $51.9M | +5% | — |
| Q2 2025 | $49.4M | +5% | — |
| Q1 2025 | $46.9M | — | — |
Q3 2026 at a glance
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Travere Therapeutics' R&D spending?
Travere Therapeutics' R&D spending was $70.3M in Q3 2026 (third quarter 2026), +17% from Q2 2026.
How has Travere Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $46.9M (Q1 2025) to $70.3M (Q3 2026).